ALX-0141 – anti-RANKL Nanobody to treat bone-loss related disorders
- ALX-0141 is being developed for the treatment of bone-loss related disorders including osteoporosis and bone metastasis
- ALX-0141 successfully completed a Phase I study in post-menopausal women
- Exclusive license agreement signed with Eddingpharm in October 2013 to develop and commercialise ALX-0141 in Mainland China, Hong Kong, Macao and Taiwan
- Ablynx is not pursuing this programme internally and is looking for licensing opportunities outside Greater China
Osteoporosis and Bone Metastasis
Osteoporosis is a progressive bone disease characterised by a decrease in bone mass and density which can lead to an increased risk for fractures. Bone metastasis, or metastatic bone disease, is a class of cancer metastases that results from primary tumor invasion to bone. Unlike haematological malignancies that originate in the blood and form non-solid tumours, bone metastasis generally arise from epithelial tumors and form a solid mass inside the bone.
ALX-0141 mode of action
ALX-0141 (41kD) specifically targets RANKL, a key mediator of bone resorption and an essential regulator of osteoclasts, the cells involved in the breakdown of bone. ALX-0141 is a trivalent Nanobody targeting RANKL and that binds to serum albumin to increase its in vivo half-life.
Ablynx is currently looking for partners to develop and commercialise ALX-0141 outside of Greater China. For further information, please contact Gosia Ciesiolka, Director Business Development.
Related presentations, abstracts and posters
Presentation at ECTS 2012: ALX-0141 increases bone mass in cynomolgus monkeys